Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.54 |
| ▸ | KDR | P35968 | 9/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.53 |
| ▸ | FLT1 | P17948 | 7/20 | 0.53 |
| ▸ | FLT4 | P35916 | 7/20 | 0.53 |
| ▸ | MET | P08581 | 3/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.53 |
| ▸ | KIT | P10721 | 3/20 | 0.53 |
| ▸ | TEK | Q02763 | 3/20 | 0.53 |
| ▸ | RET | P07949 | 3/20 | 0.53 |
| ▸ | PLK4 | O00444 | 2/20 | 0.53 |
| ▸ | GAK | O14976 | 2/20 | 0.53 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.53 |
| ▸ | STK10 | O94804 | 2/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.53 |
| ▸ | LCK | P06239 | 2/20 | 0.53 |
| ▸ | FYN | P06241 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3208867 | 0.92 | KDR (0.56) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL11953086 | 0.91 | RET (0.52) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL1401709 | 0.90 | KDR (0.53) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL1401676 | 0.90 | KDR (0.48) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL2922369 | 0.87 | KDR (0.70) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL1401725 | 0.86 | PIK3CD (0.48) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL2958541 | 0.86 | EGFR (0.54) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL3193278 | 0.85 | KDR (0.69) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL4382067 | 0.85 | EGFR (0.55) | EGFRKDRKITSRC | |
| SCHEMBL3200926 | 0.82 | KDR (0.77) | EGFRKDRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | claimed |
| EP-1790340-A2 | Combination chemotherapy | AstraZeneca AB (SE) | 2007-05-30 | — | — | EP | claimed |
| EP-1272186-B1 | THERAPEUTIC COMBINATIONS OF ANTIHYPERTENSIVE AND ANTIANGIOGENIC AGENTS | ASTRAZENECA AB (SE) | 2007-02-28 | — | — | EP | claimed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | claimed |
| EP-1154774-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | claimed |
| US-20030144298-A1 | Using a combination of an angiogenisis inhibitor and a hypotensive agent for use in treating diseases associated with angiogenesis; an endothelial growth factor receptor tyrosine kinase inhibitor; antidiabetic, -arthritis agents | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | claimed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| US-7829573-B2 | Therapeutic combinations of antihypertensive and antiangiogenics agents | ASTRAZENECA AB (SE) | 2010-11-09 | — | — | US | disclosed |
| EP-1553097-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20100029673-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| EP-1658849-A2 | Therapeutic combinations of antihypertensive and antiangiogenic agents | AstraZeneca AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| EP-1154774-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| US-20030144298-A1 | Using a combination of an angiogenisis inhibitor and a hypotensive agent for use in treating diseases associated with angiogenesis; an endothelial growth factor receptor tyrosine kinase inhibitor; antidiabetic, -arthritis agents | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | EGFR 500/4885KDR 3/4885FGFR1 159/4885 |
| US-20030144298-A1 | Using a combination of an angiogenisis inhibitor and a hypotensive agent for use in treating diseases associated with angiogenesis; an endothelial growth factor receptor tyrosine kinase inhibitor; antidiabetic, -arthritis agents | TEK, TIE1, FLT1 | EGFR 51/4885KDR 5/4885FGFR1 9/4885 |
| US-20100029673-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | SRC, CHUK, CTTN | EGFR 233/4885KDR 10/4885FGFR1 52/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | EGFR 549/4885KDR 4/4885FGFR1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.